GLP1RAs administration demonstrates substantial insulin sensitivity enhancement and profound weight loss effect and thus inhibits a vicious cycle among obesity, IR, hyperandrogenism, which promise its benefits in PCOS patients [15, 20, 22, 50]. Here, INS is linked to obesity disorder.